Available technologies

Inducible ZnT8 transgenic mouse

Reference number: 7935

Proposed use

Diabetes research.

Technology overview

The relevant sequence in the transgenic incorporates a bidirectional tetracyclin regulated promoter, which drives expression of both human ZnT8 Myc and firefly luciferase. This allows ZnT8 expression to be controlled by tetracycline and the sites at which it occurs to be easily identified. Zinc transporter 8 (ZnT8), encoded by SLC30A8, is chiefly expressed within pancreatic islet cells, where it mediates zinc (Zn2[1]) uptake into secretory granules. Although a common nonsynonymous polymorphism (R325W), which lowers activity, is associated with increased type 2 diabetes (T2D) risk, rare inactivating mutations in SLC30A8 have been reported to protect against T2D.

Benefits

  • ZnT8 expression controlled by tetracycline and the sites at which it occurs are easily identified.
  • Associated with increased type 2 diabetes (T2D) risk
  • Rare inactivating mutations in SLC30A8 have been reported to protect against T2D.

Intellectual property information

Reagent/material

Inventor information

Professor Guy Rutter

Download datasheet

contact

Alexandra Skeaping

Industry Partnerships and Commercialisation Officer, Medicine

a.skeaping@imperial.ac.uk

+44 (0)20 7594 7021

Contact us about this technology

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London